COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to a compound represented by formula 1 as an adenosine A2areceptor antagonist, stereoisomers thereof, pharmaceutically acceptable salts thereof, a method using the same, a medicinal use thereof, and a pharmaceutical composition including the same..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 28. Feb. Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

LEE CHANG SIK [VerfasserIn]
LEE JAEWON [VerfasserIn]
LEE JAE YOUNG [VerfasserIn]
PARK YESONG [VerfasserIn]
GWAK DALYONG [VerfasserIn]
KIM HYUNJIN MICHAEL [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
C07D: Heterocyclic compounds (macromolecular compounds c0 (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-02-28, Last update posted on www.tib.eu: 2024-03-14, Last updated: 2024-03-22

Patentnummer:

EP4326724

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA000026824